Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecentriq with trimodal therapy in muscle-invasive bladder cancer
NCT03620435Phase 2Unknown
- Sponsor
- McGill University Health Centre
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in Muscle Invasive Bladder Cancer (MIBC), sponsored by McGill University Health Centre. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT03620435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620435.